A Causal Relationship Between Genetically Proxied Inhibition of HMGCR, NPC1L1, and PCSK9 and Cancers

A Causal Relationship Between Genetically Proxied Inhibition of HMGCR, NPC1L1, and PCSK9 and Cancers

Saved in:

Bibliographic Details
Main Authors:	Xin Wang, Yiyao Zeng, Zihan Xu, Xiangyue Meng, Jie Chen
Format:	Article
Language:	English
Published:	Wiley 2025-06-01
Series:	MedComm – Oncology
Online Access:	https://doi.org/10.1002/mog2.70026
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
by: Si Fang, et al.
Published: (2023-01-01)

Current Evidence and Future Directions of PCSK9 Inhibition
by: Jiaqian Xu, et al.
Published: (2021-02-01)

PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
by: Simon Rauterberg, et al.
Published: (2025-01-01)

Inhibition of NPC1L1 disrupts adaptive responses of drug‐tolerant persister cells to chemotherapy
by: Zhe Zhang, et al.
Published: (2022-01-01)

PCSK9 Inhibitors: The Evolving Future
by: Bijay Mukesh Jeswani, et al.
Published: (2024-11-01)

Genetic Characterization of the Immortalized Human Nasopharyngeal Carcinoma Cell Line NPC/HK1
by: Anna Makowska, et al.
Published: (2025-02-01)

Genetic screening of malay familial hypercholesterolemia patient for LDLRAP1/PCSK9/APOB mutations via whole exome sequencing
by: Muhammad-Redha Abdullah-Zawawi, et al.
Published: (2025-03-01)

L-methionine promotes CD8+ T cells killing hepatocellular carcinoma by inhibiting NR1I2/PCSK9 signaling
by: Chengsha Yuan, et al.
Published: (2025-06-01)

PCSK9 in T-cell function and the immune response
by: Yuying Wang, et al.
Published: (2024-12-01)

Lipid metabolism reprograming by SREBP1‐PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy
by: Mengyi Lao, et al.
Published: (2025-08-01)

HIIT and MICT mitigate endothelial dysfunction in early atherosclerotic mice via PCSK9 inhibition
by: Guochun Liu, et al.
Published: (2025-08-01)

Immune checkpoint inhibition in NPC: A comprehensive review of PD-L1 overexpression and treatment responses
by: Madhan Krishnan, et al.
Published: (2024-12-01)

Novel insights into the association between genetically proxied inhibition of proprotein convertase subtilisin/kexin type 9 and risk of sarcopenia
by: Hongyan Jiang, et al.
Published: (2024-12-01)

CO18 | Relationship between gut permeability and PCSK9 in heterozygous familial hypercholesterolemia
Published: (2025-08-01)

Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases
by: Zhenzhen Li, et al.
Published: (2024-11-01)

Correction: Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations.
by: Mahtaab Hayat, et al.
Published: (2021-01-01)

Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
by: S. Yu. Volkova, et al.
Published: (2023-03-01)

Taurochenodeoxycholic acid suppresses the progression of glioblastoma via HMGCS1/HMGCR/GPX4 signaling pathway in vitro and in vivo
by: Xiumin Xue, et al.
Published: (2025-04-01)

The relationship between oxLDL, sLOX-1, PCSK9 and carotid intima-media thickness in patients with prediabetes and type 2 diabetes
by: Zeki Dogan, et al.
Published: (2025-02-01)

Case report: Rapid clinical improvement of anti-HMGCR immune-mediated necrotizing myopathy treated with efgartigimod
by: Quantao Zeng, et al.
Published: (2024-11-01)

Methionine Metabolism Dictates PCSK9 Expression and Antitumor Potency of PD‐1 Blockade in MSS Colorectal Cancer
by: Qi‐Long Wang, et al.
Published: (2025-05-01)

ApoE4 requires lipidation enhancement to resolve cellular lipid and protein abnormalities following NPC1 inhibition
by: Erika Di Biase, et al.
Published: (2025-04-01)

Taurine alleviates dysfunction of cholesterol metabolism under hyperuricemia by inhibiting A2AR-SREBP-2/CREB/HMGCR axis
by: Beibei Chen, et al.
Published: (2025-02-01)

Research of the Common-mode Voltage Inhibition for Three-level NPC Inverter
by: DING Guanyuan, et al.
Published: (2015-01-01)

Mechanisms of action and therapeutic potential of PCSK9-regulating drugs
by: Chenrui Qi, et al.
Published: (2025-12-01)

Early effects of PCSK9 inhibitors: evolocumab versus alirocumab
by: Su-Hyun Bae, et al.
Published: (2025-03-01)

Engineering chimeric PCSK9 for a vaccine against atherosclerosis
by: Špela Malenšek, et al.
Published: (2025-09-01)

Prospects of Using PCSK9 Inhibitors for Acute Coronary Syndrome
by: A. M. Namitokov, et al.
Published: (2024-04-01)

Circulating citrate as a mediator in the relationship between HMGCR inhibitors and chronic hepatitis B: a Mendelian randomization study
by: Lili Zhang, et al.
Published: (2025-04-01)

THE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) IN THE PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
by: Алексей Михайлович Чаулин, et al.
Published: (2019-12-01)

Genetically proxied inhibition of Phosphodiesterase-5 and cancer risks: A drug-target Mendelian randomization analysis
by: Kefu Tang, et al.
Published: (2025-07-01)

Hypecotumines A-D, new isoquinoline alkaloids with potential PCSK9 inhibition activity from Hypecoum erectum L.
by: Yinling Wei, et al.
Published: (2024-10-01)

Effectiveness of Red Watermelon in Preventing Atherosclerosis Through the Role of Lipids, PCSK9, LOX-1, CD36, and ABCA1 in Wistar Rats
by: Mochamad Bahrudin, et al.
Published: (2025-06-01)

Blockade of colon cancer metastasis via single and double silencing of PCSK7/PCSK9: enhanced T cells cytotoxicity in mouse and human
by: Delia Susan-Resiga, et al.
Published: (2025-06-01)

PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease
by: article Editorial
Published: (2023-12-01)

The function of PCSK9 in doxorubicin-induced cardiotoxicity and its underlying mechanism
by: Shuai Shi, et al.
Published: (2025-07-01)

MicroRNA-1912 regulates cholesterol homeostasis by targeting PCSK9
by: Chan Joo Lee, et al.
Published: (2025-09-01)

Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease
by: Haixia Tang, et al.
Published: (2025-08-01)

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
by: Maram H. Abduljabbar
Published: (2024-11-01)

PCSK9-promoted LDLR degradation: Recruitment or prevention of essential cofactors?
by: Rong Li, et al.
Published: (2025-06-01)